Progesterone receptor loss identifies hormone receptor-positive and HER2-negative breast cancer subgroups at higher risk of relapse: a retrospective cohort study
Authors Sun J, Wu S, Li F, Lin H, He Z
Received 20 October 2015
Accepted for publication 1 February 2016
Published 21 March 2016 Volume 2016:9 Pages 1707—1713
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Dekuang Zhao
Peer reviewer comments 2
Editor who approved publication: Professor Daniele Santini
Jia-Yuan Sun,1,* San-Gang Wu,2,* Feng-Yan Li,1 Huan-Xin Lin,1 Zhen-Yu He1
1Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, People’s Republic of China; 2Department of Radiation Oncology, Xiamen Cancer Center, The First Affiliated Hospital of Xiamen University, Xiamen, People’s Republic of China
*These authors contributed equally to this work
Background: To assess the prognostic value of progesterone receptor (PR) expression in patients with hormone receptor-positive and human epidermal growth factor receptor 2 (HER2)-negative breast cancer subgroups.
Methods: A retrospective review of breast cancer patients who underwent mastectomy or breast-conserving surgery between January 1998 and December 2007 was performed. The prognostic impact of PR status on disease-free survival (DFS) was analyzed.
Results: Of the 1,301 patients included in this study, the median follow-up time was 64 months, and the median age was 46 years. There were 18.4% of patients (n=219) with PR negative (PR–) cancer. Women with PR– breast cancer were more likely to be postmenopausal (P<0.001) and have pN3 stage (P=0.031) and Stage III (P=0.049) cancer. Cox regression univariate and multivariate analysis showed that PR status was a significant prognostic factor for DFS. Patients with PR– status had poorer DFS (hazard ratio =1.626, 95% confidence interval =1.060–2.497, P=0.026). The 5-year DFS for patients with PR– and PR+ breast cancer was 79.4% and 86.2%, respectively, and the 8-year DFS for patients with PR– and PR+ breast cancer was 69.6% and 78.1%, respectively (P=0.012). A significant difference in DFS was observed between PR– and PR+ disease in patients with node-negative cancer, but was not for patients with lymph node metastasis (P=0.242). In premenopausal patients, DFS varied significantly by PR status (P=0.049). A marginally significant difference in DFS between the PR– and PR+ disease was seen in postmenopausal patients (log rank P=0.065).
Conclusion: Lack of PR expression is associated with worse survival in patients with hormone receptor-positive and HER2-negative breast cancer subgroups.
Keywords: breast cancer, breast cancer subtype, progesterone receptor, prognosis, recurrence
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]